Global Cardiovascular Risk Reduction Market – Industry Trends and Forecast to 2029

Market Analysis and Size

In recent years, the cardiovascular risk reduction market is anticipated to grow rapidly during the forecast period. Cardiovascular illnesses are the major causes of death worldwide. Ischemic heart disease is responsible for 16 percent of all fatalities worldwide, according to the World Health Organization's (WHO) 2020 updates. According to an article Heart failure (HF) in France, chronic heart failure therapeutic management and risk of cardiac decompensation in a real-life setting, approximately one million people in France will be affected by HF; nearly 70,000 people will die from HF, and more than 150,000 people will be hospitalized despite well-defined treatment management.

Data Bridge Market Research analyses that the cardiovascular risk reduction market was valued at USD 71.96 billion in 2021 and is expected to reach USD 96.98 billion by 2029, registering a CAGR of 3.80% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Cardiovascular diseases (CVDs) are illnesses that affect the heart and circulatory system. Hypertension, cerebrovascular heart disease, inflammatory heart disease, ischemic heart disease, and rheumatic heart disease are some of the most common cardiovascular illnesses. High blood pressure causes hypertensive heart disease.

Report Scope and Market Segmentation

Cardiovascular Risk Reduction Market Dynamics

Drivers

• Increasing prevalence of cardiovascular diseases

The rising prevalence of cardiovascular diseases is estimated to enhance the market's growth. According to World Health Organization (WHO), CVDs claimed the lives of 17.9 million individuals worldwide in 2019, accounting for 32% of all deaths. Heart attacks and strokes were responsible for 85 percent of these deaths.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of cardiovascular risk reduction market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get cardiovascular disease, further estimated to enhance the market’s growth rate.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the cardiovascular risk reduction market. Additionally, changing lifestyle of people and rising level of disposable income will result in the expansion of cardiovascular risk reduction market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the cardiovascular risk reduction market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the cardiovascular risk reduction market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the cardiovascular risk reduction market. Additionally, strict regulatory policies and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This cardiovascular risk reduction market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiovascular risk reduction market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Cardiovascular risk reduction market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Cardiovascular Risk Reduction Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The cardiovascular risk reduction market was hampered by the supply chain slowness.

Global Cardiovascular Risk Reduction Market Scope

The cardiovascular risk reduction market is segmented on the basis of diseases, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diseases

• Hypertension
• Dyslipidemia
• Diabetes
• Others

Treatment

• Antiplatelet Agents
• Beta-Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cardiovascular Risk Reduction Market Regional Analysis/Insights

The cardiovascular risk reduction market is analysed and market size insights and trends are provided by country, diseases, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cardiovascular risk reduction market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the cardiovascular risk reduction market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to increasing number of generic manufacturer in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Cardiovascular Risk Reduction Market Share Analysis

The cardiovascular risk reduction market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiovascular risk reduction market.

Some of the major players operating in the cardiovascular risk reduction market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• AstraZeneca (UK)
• Johnson & Johnson (US)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd. (India)
• Bristol-Myers Squibb Company (US)
• Eli Lilly and Company (US)
• Cipla Inc. (US)
• Endo International plc (Ireland)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (UK)

SKU-54416